. 2022 Jul;11(7):1247–1267. doi: 10.21037/tlcr-22-527

Table 4. Summary of randomized phase II/III trials of EGFR tyrosine kinase inhibitors in the adjuvant setting.

Trial	Phase	Population	Arms	N	mDFS (months)	HR	mOS (months)	HR
RADIANT	III	IB–IIIA EGFR+	Erlotinib for 2 years	623	50.5	0.9	NR	1.09
RADIANT	III	IB–IIIA EGFR+	Placebo	250	48.2	0.9	NR	1.09
BR19	III	IB–IIIA EGFR+	Gefitinib for 2 years	251	50.4	1.22	5.1	1.24
BR19	III	IB–IIIA EGFR+	Placebo	252	NR	1.22	NR	1.24
CTONG1104/ADJUVANT	III	II–IIIA EGFR+	Gefitinib for 2 years	111	30.8	0.56	75.5	0.92
CTONG1104/ADJUVANT	III	II–IIIA EGFR+	Cisplatin/vinorelbine	111	19.8	0.56	62.8	0.92
EVAN	II	IIIA EGFR+	Erlotinib for 2 years	51	42.4	0.268	NR	0.165
EVAN	II	IIIA EGFR+	Cisplatin/vinorelbine	51	21	0.268	NR	0.165
ADAURA	III	IB–IIIA EGFR+	Osimertinib for 3 years	339	NR	0.17	NR	0.4
ADAURA	III	IB–IIIA EGFR+	Placebo	343	20.4	0.17	NR	0.4
EVIDENCE	III	II–IIIA EGFR+	Icotinib for 2 years	151	47.0	0.36	NR	0.91
EVIDENCE	III	II–IIIA EGFR+	Intravenous chemotherapy	132	22.1	0.36	NR	0.91

HR, hazard ratio; EGFR+, EGFR-mutated; mDFS, median disease-free survival; mOS, median overall survival; NR, not reached.